A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR
mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376
and characterize its pharmacokinetic profile.